Redhill Biopharma
RDHL
$1.48
Share price
-9.20%
Change (1 day)
-84.94%
Change (1 year)
Categories
Revenue for Redhill Biopharma (RDHL)
Revenue in 2022: $61.8 Million USD
According to Redhill Biopharma's latest financial reports the company's current revenue (TTM 
) is $35.74 Million USD. In 2022 the company made a revenue of $61.8 Million USD a decrease over the revenue in the year 2021 that were of $85.75 Million USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Redhill Biopharma from 2012 to 2022
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2022 | $61.8 M | -27.94% |
| 2021 | $85.75 M | 33.25% |
| 2020 | $64.35 M | 923.03% |
| 2019 | $6.29 M | -24.75% |
| 2018 | $8.36 M | 108.63% |
| 2017 | $4 M | 3867.33% |
| 2016 | $0.1 M | 3266.67% |
| 2015 | $0 M | -99.96% |
| 2014 | $7.01 M | 58350% |
| 2013 | $0.01 M | -25% |
| 2012 | $0.01 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $47.39 B | 132,501.07% | 🇫🇷 France |
 Merck MRK | $63.92 B | 178,727.81% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $40.58 B | 113,444.79% | 🇬🇧 UK |
 Taro Pharmaceutical TARO | $0.61 B | 1,608.85% | 🇮🇱 Israel |
 Teva Pharmaceutical Industries TEVA | $16.61 B | 46,382.03% | 🇮🇱 Israel |